Becton, Dickinson and Company $BDX Shares Sold by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 24.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 230 shares of the medical instruments supplier’s stock after selling 75 shares during the period. Union Bancaire Privee UBP SA’s holdings in Becton, Dickinson and Company were worth $40,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Saudi Central Bank acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $26,000. Smallwood Wealth Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $27,000. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC lifted its stake in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the first quarter worth $31,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $190.90 on Thursday. The firm has a 50-day simple moving average of $188.71 and a 200-day simple moving average of $188.20. The stock has a market capitalization of $54.72 billion, a price-to-earnings ratio of 34.33, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 74.82%.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,185 shares of the company’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock valued at $562,036 in the last three months. 0.36% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price objective for the company. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Piper Sandler restated a “neutral” rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Argus upped their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.